Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) is set to present its research on using flow cytometry for diagnosing lung diseases at the CHEST 2022 conference from Oct. 16-19, 2022. The presentation, led by PhD Lydia Bederka, will focus on Sputum Analysis By Flow Cytometry To Assess Lung Health on Oct. 19, highlighting the development of its product, CyPath® Lung, which detects early-stage lung cancer with 92% sensitivity and 87% specificity.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has secured approximately $7.7 million from the recent exercise of warrants related to its September 6, 2022 public offering. This was achieved through 725,576 tradeable warrants at $7.35 per share and 310,910 non-tradable warrants at $7.656 per share. Overall, the company has gathered about $15.6 million in gross proceeds. The funds will support the commercialization of CyPath® Lung and other developmental projects.
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) announced a publication in PLOS ONE regarding their flow cytometry research on sputum analysis for lung health diagnostics. The study introduces an innovative method for detecting lung cancer and potentially other diseases like COPD and asthma. President and CEO Maria Zannes emphasized the significance of this noninvasive diagnostic approach, stating it may enhance overall diagnostic accuracy, reduce unnecessary procedures, and lower medical costs. bioAffinity's CyPath® Lung test, known for its high sensitivity and specificity, supports early lung cancer detection.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has successfully completed its initial public offering (IPO), raising approximately $7.8 million through the sale of 1,282,600 units. Each unit consists of one share of common stock and two types of warrants, with exercise prices set at $7.35 and $7.656. The underwriters have an option to purchase up to 192,390 additional shares and/or warrants. The offering, managed by WallachBeth Capital and Craft Capital Management, aims to enhance bioAffinity's efforts in developing noninvasive cancer diagnostics.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced the successful completion of its IPO, raising approximately $7.8 million by offering 1,282,600 units that include common stock and warrants. The IPO allows for a 45-day option for underwriters to purchase additional shares. The funds will be used to expand operations, pursue regulatory approvals, and continue research on early-stage cancer diagnostics and therapeutics like CyPath® Lung. This test enables non-invasive early detection of lung cancer, enhancing survival rates.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has successfully priced its initial public offering (IPO) of 1,282,600 units at $6.125 per unit, aiming to raise approximately $7.86 million before expenses. Each unit includes one share of common stock and two warrants with exercise prices of $7.35 and $7.656. The IPO proceeds will primarily fund the commercialization of its diagnostic test, CyPath® Lung, which has demonstrated 92% sensitivity and 87% specificity in detecting lung cancer. The shares begin trading on September 1, 2022, under the ticker symbols BIAF and BIAFW.
bioAffinity Technologies, Inc. announced the pricing of its initial public offering (IPO) at $6.125 per unit, raising approximately $7,855,925 before expenses. The offering includes 1,282,600 units, each consisting of one share of common stock and two warrants for future stock purchase. The IPO is set to trade on the Nasdaq under symbols BIAF and BIAFW starting September 1, 2022. Proceeds will support the commercialization of the CyPath® Lung diagnostic test, which demonstrated 92% sensitivity and 87% specificity.